Suppr超能文献

口服吸入和鼻腔给药产品中可提取物和可浸出物的最佳实践:PQRI建议概述

Best practices for extractables and leachables in orally inhaled and nasal drug products: an overview of the PQRI recommendations.

作者信息

Norwood Daniel L, Paskiet Diane, Ruberto Michael, Feinberg Thomas, Schroeder Alan, Poochikian Guirag, Wang Qingxi, Deng Tian Jing, DeGrazio Fran, Munos Melinda K, Nagao Lee M

机构信息

Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.

出版信息

Pharm Res. 2008 Apr;25(4):727-39. doi: 10.1007/s11095-007-9521-z. Epub 2008 Jan 9.

Abstract

The Product Quality Research Institute Leachables and Extractables Working Group includes pharmaceutical development scientists representing industry, government, and academia. The Working Group was created and constituted to address scientific and regulatory questions concerning the pharmaceutical development process for Orally Inhaled and Nasal Drug Products (OINDP) related to organic extractables and leachables. This effort has resulted in the creation of a detailed "Recommendation Document", which was submitted to the U.S. FDA for consideration in September 2006. The recommendations include proposed safety and analytical thresholds for leachables and extractables, as well as detailed "best practice" recommendations for various aspects of the OINDP pharmaceutical development process, including: materials selection for OINDP container closure system components, Controlled Extraction Studies, Leachables Studies, and Routine Extractables Testing. The Working Group's processes and the detailed and comprehensive recommendations that resulted from those processes, demonstrate that the Product Quality Research Institute collaborative process can result in consensus science-based and data driven recommendations that could have a positive effect on patient care. It is anticipated that the Working Group's recommendations will also contribute to the new "Quality by Design" pharmaceutical development paradigm. This commentary summarizes the best practice recommendations within the context of an overall pharmaceutical development process.

摘要

产品质量研究机构可沥滤物与可提取物工作组包括来自行业、政府和学术界的药物研发科学家。该工作组的设立旨在解决与口服吸入和鼻腔给药产品(OINDP)的有机可提取物和可沥滤物相关的药物研发过程中的科学和监管问题。这项工作成果是一份详细的《建议文件》,已于2006年9月提交给美国食品药品监督管理局(FDA)以供审议。这些建议包括可沥滤物和可提取物的拟议安全和分析阈值,以及OINDP药物研发过程各方面的详细“最佳实践”建议,包括:OINDP容器密封系统组件的材料选择、可控提取研究、可沥滤物研究和常规可提取物测试。工作组的流程以及这些流程产生的详细全面的建议表明,产品质量研究机构的协作流程能够产生基于科学共识和数据驱动的建议,这可能对患者护理产生积极影响。预计工作组的建议也将有助于新的“质量源于设计”药物研发模式。本评论在整体药物研发过程的背景下总结了最佳实践建议。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验